Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.66 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.47 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496280 | 0.91 | KDR (0.53) | KDRFLT1ACLYKMT2AMEN1 | |
| SCHEMBL1347578 | 0.91 | KDR (0.55) | KDRFLT1KMT2AMEN1OPRL1 | |
| SCHEMBL1496367 | 0.91 | KDR (0.53) | KDRFLT1ACLYKMT2AMEN1 | |
| SCHEMBL1496284 | 0.89 | KDR (0.52) | KDRFLT1NPC1ACLYKMT2A | |
| SCHEMBL1496305 | 0.88 | KDR (0.50) | KDRFLT1NPC1ACLYKMT2A | |
| SCHEMBL1496282 | 0.87 | KDR (0.64) | KDRFLT1NPC1TSHRACLY | |
| SCHEMBL1496364 | 0.87 | HTR2C (0.53) | KDRFLT1KMT2AALDH1A1GAA | |
| SCHEMBL1496360 | 0.87 | KDR (0.57) | KDRFLT1KMT2AMEN1PABPC1 | |
| SCHEMBL1496381 | 0.87 | NSD2 (0.56) | KDRKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL1496334 | 0.85 | KDR (0.56) | KDRNPC1KMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | claimed |
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | claimed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | claimed |
| EP-1854787-A1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-14 | — | — | EP | claimed |
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897774-B2 | Cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | disclosed |
| EP-1854787-B1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1854787-A1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
| EP-1854787-A1 | NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021064-A1 | Novel cyclic compound having quinolylalkylthio group | SQOR, QSOX1, SQLE | KDR 3463/4885FLT1 2060/4885NPC1 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.